Preimplantation Genetic Testing Market - Global Forecast 2026-2032 | Market to Reach USD 1.97 Billion as NGS, AI-Enabled Labs, and Precision IVF Drive 12.36% CAGR
Dublin, Nov. 19, 2026 (GLOBE NEWSWIRE) -- "Preimplantation Genetic Testing Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.
The preimplantation genetic testing (PGT) market research report provides a comprehensive assessment of industry growth, technology adoption, clinical applications, regional dynamics, and strategic opportunities. The market is projected to reach USD 981.15 million in 2026 and expand at a CAGR of 12.36% to USD 1.97 billion by 2032. Its insights support strategic planning, competitive positioning, and market-entry decisions across fertility services, reproductive genetics, and laboratory technologies.
Market Overview and Growth Drivers
PGT is an increasingly important component of assisted reproductive technology, enabling fertility centers to assess embryos for chromosomal aneuploidy, monogenic disorders, and structural rearrangements before transfer. Key testing categories include:
Laboratory workflows are supported by next-generation sequencing (NGS), polymerase chain reaction, single-nucleotide polymorphism analysis, and whole-genome amplification. Demand is reinforced by infertility prevalence, delayed parenthood, inherited-disease awareness, and expanding access to genomic medicine. The World Health Organization estimates that approximately one in six adults experiences infertility during their lifetime.
Transformative Industry Shifts
Advances in NGS, embryo biopsy, vitrification, and integrated fertility-clinic data systems are improving testing capabilities. Trophectoderm biopsy at the blastocyst stage is widely used because it permits analysis of multiple cells while preserving the inner cell mass.
Clinical care is also shifting toward evidence-led, patient-specific planning supported by genetic counseling, laboratory accreditation, transparent reporting, and multidisciplinary review. However, mosaicism, reimbursement gaps, regulatory differences, ethical considerations, and test limitations continue to influence adoption. Understanding these constraints enables stakeholders to identify viable opportunities while mitigating clinical, regulatory, and reputational risks.
Artificial Intelligence and Digital Innovation
Artificial intelligence is emerging across embryo imaging analytics, laboratory quality control, workflow automation, and clinical decision support. Computer vision can improve consistency in embryo morphology assessment, while AI-enabled systems can monitor sample handling, flag workflow inconsistencies, and strengthen chain-of-custody controls.
Near-term value is expected to center on reducing variability, accelerating turnaround times, improving documentation, and supporting explainable decisions. Prospective validation remains essential before AI outputs can serve as standalone clinical determinants.
Regional Market Insights
Strategic Market Group and Country Perspectives
The European Union and G7 combine advanced biomedical infrastructure with established regulatory oversight. BRICS markets offer significant growth potential through large patient populations and expanding fertility networks. ASEAN adoption is supported by medical tourism hubs, while GCC countries present opportunities for PGT-M and carrier-screening-linked IVF pathways.
The United States leads in commercial availability and laboratory scale. The United Kingdom, Germany, France, Italy, and Spain remain influential European markets, while China, India, Japan, South Korea, and Australia contribute substantial clinical and technology capacity. Country-level comparisons provide practical guidance for prioritizing partnerships, investments, and localized access strategies.
Strategic Priorities for Industry Leaders
Key Takeaways from This Report
Key Attributes:
Key Topics Covered:
1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Preimplantation Genetic Testing Market, by Test Type
7.1. Introduction
7.2. PGT-A (Aneuploidy)
7.3. PGT-M (Monogenic Disorders)
7.4. PGT-SR (Structural Rearrangements)
7.5. PGT-HLA (Human Leukocyte Antigen Matching)
8. Preimplantation Genetic Testing Market, by Technology Type
8.1. Introduction
8.2. Comparative Genomic Hybridization
8.3. Fluorescent In-Situ Hybridization
8.4. Next-Generation Sequencing
8.5. PCR-Based Testing
8.6. Single-Nucleotide Polymorphism
9. Preimplantation Genetic Testing Market, by Offering
9.1. Introduction
9.2. Instruments
9.3. Reagents & Consumables
9.3.1. Kits
9.3.2. Probes
10. Preimplantation Genetic Testing Market, by Procedure Stage
10.1. Introduction
10.2. Embryo Biopsy
10.3. Polar Body Biopsy
10.4. Blastocyst Biopsy
11. Preimplantation Genetic Testing Market, by Application
11.1. Introduction
11.2. Aneuploidy Screening
11.3. Monogenic Diseases
11.4. IVF Prognosis
12. Preimplantation Genetic Testing Market, by End User
12.1. Introduction
12.2. Diagnostic Laboratories
12.3. Fertility Clinics
12.4. Hospitals
12.5. Research Institutes
13. Preimplantation Genetic Testing Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. Europe
13.4. North America
13.5. Africa
13.6. Latin America
13.7. Middle East
14. Preimplantation Genetic Testing Market, by Group
14.1. Introduction
14.2. NATO
14.3. G7
14.4. European Union
14.5. BRICS
14.6. ASEAN
14.7. GCC
15. Preimplantation Genetic Testing Market, by Country
15.1. Introduction
15.2. United States
15.3. China
15.4. Germany
15.5. Japan
15.6. India
15.7. United Kingdom
15.8. France
15.9. Australia
15.10. Canada
15.11. Italy
15.12. South Korea
15.13. Brazil
15.14. Russia
15.15. Mexico
15.16. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories
17.2. Agilent Technologies, Inc.
17.3. Bio-Techne Corporation
17.4. Bioarray S.L.
17.5. EUROPE IVF International s.r.o.
17.6. F. Hoffmann-La Roche AG
17.7. Genea Limited
17.8. GENETiKS
17.9. Illumina, Inc.
17.10. Invicta Genetics
17.11. Invitae Corporation
17.12. Juno Genetics, US Inc.
17.13. Laboratory Corporation of America Holdings
17.14. MedGenome Labs Ltd.
17.15. Merck KGaA
17.16. Natera, Inc.
17.17. NextGen Genetics Holdings, LLC
17.18. Ovation Fertility
17.19. PacGenomics
17.20. PerkinElmer, Inc.
17.21. Progyny, Inc.
17.22. Qiagen N.V.
17.23. Quest Diagnostics Incorporated
17.24. Reproductive Genetic Innovations, LLC
17.25. SEQUENCE46, LLC
17.26. Sysmex Corporation
17.27. Takara Bio Inc.
17.28. The Cooper Companies Inc.
17.29. Thermo Fisher Scientific Inc.
17.30. Vitrolife Sweden AB
17.31. Yikon Genomics (Shanghai) Co., Ltd.
18. Key Experts
List of Figures [23]
List of Tables [298]
For more information about this report visit https://www.researchandmarkets.com/r/ccvpgc
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.